Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Advanced NeuroStimulation Systems (ANS) is a medical technology company specializing in the design, development, and manufacturing of implantable neuromodulation devices. The company's primary focus is on spinal cord stimulation (SCS) and deep brain stimulation (DBS) systems used to manage chronic pain and movement disorders. Their product portfolio includes the Genesis and Eon neurostimulation systems, which deliver electrical pulses to the spinal cord or brain to mask pain signals or regulate abnormal neural activity. In 2005, ANS was acquired by St. Jude Medical for approximately $1.3 billion, significantly expanding St. Jude's presence in the neuromodulation market. Today, the legacy of ANS continues as part of Abbott's neuromodulation division following Abbott's acquisition of St. Jude Medical.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Advanced NeuroStimulation Systems.